Regulus Therapeutics (NASDAQ:RGLS) Coverage Initiated at StockNews.com

Investment analysts at StockNews.com began coverage on shares of Regulus Therapeutics (NASDAQ:RGLS) in a research report issued on Tuesday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

RGLS has been the topic of a number of other research reports. Leerink Partnrs restated an “outperform” rating on shares of Regulus Therapeutics in a report on Monday, March 18th. Canaccord Genuity Group lowered their price objective on Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a research report on Tuesday, March 19th. Wells Fargo & Company boosted their target price on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the company an “equal weight” rating in a research note on Wednesday, March 13th. HC Wainwright restated a “buy” rating and issued a $9.00 price objective on shares of Regulus Therapeutics in a research note on Monday, March 25th. Finally, SVB Leerink assumed coverage on Regulus Therapeutics in a research note on Monday, March 18th. They issued an “outperform” rating and a $6.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $7.25.

Regulus Therapeutics Trading Down 8.6 %

Shares of RGLS opened at $2.34 on Tuesday. The company has a market capitalization of $153.18 million, a price-to-earnings ratio of -1.47 and a beta of 1.57. The stock has a 50 day moving average of $2.08 and a 200 day moving average of $1.58. Regulus Therapeutics has a 12 month low of $1.08 and a 12 month high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last posted its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, hitting analysts’ consensus estimates of ($0.40). As a group, equities research analysts predict that Regulus Therapeutics will post -0.52 earnings per share for the current year.

Hedge Funds Weigh In On Regulus Therapeutics

A number of institutional investors have recently modified their holdings of RGLS. Renaissance Technologies LLC boosted its stake in Regulus Therapeutics by 498.2% in the first quarter. Renaissance Technologies LLC now owns 133,400 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 111,100 shares in the last quarter. Northern Trust Corp lifted its position in Regulus Therapeutics by 42.9% during the first quarter. Northern Trust Corp now owns 168,172 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 50,518 shares during the period. Dimensional Fund Advisors LP acquired a new position in Regulus Therapeutics during the third quarter valued at $54,000. Commonwealth Equity Services LLC increased its holdings in Regulus Therapeutics by 52.3% in the third quarter. Commonwealth Equity Services LLC now owns 33,500 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 11,500 shares in the last quarter. Finally, BlackRock Inc. increased its holdings in Regulus Therapeutics by 108.5% in the third quarter. BlackRock Inc. now owns 45,614 shares of the biopharmaceutical company’s stock valued at $78,000 after buying an additional 23,738 shares in the last quarter. 92.38% of the stock is owned by hedge funds and other institutional investors.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.